Status:
UNKNOWN
Evaluation of Ocular Surface Changes Following RF Electrocoagulation Treatment of the Periorbital Region
Lead Sponsor:
Ophthalmic Consultants of Long Island
Conditions:
Skin Laxity
Meibomian Gland Dysfunction
Eligibility:
All Genders
40-70 years
Brief Summary
This protocol will evaluate THERMIeyes® for its ability to treat periorbital skin laxity and wrinkles and monitor ocular surface changes and their effect on evaporative dry eye associated with MGD.
Detailed Description
Subjects with skin laxity and evaporative dry eye will be recruited for enrollment in this study. Subjects must present with subjective and objective indicators for periorbital skin laxity and wrinkle...
Eligibility Criteria
Inclusion
- Subjects must be 40-70 Inclusive; Male or Female
- Subjects must demonstrate subjective and objective indicators for periorbital skin laxity and wrinkle grade of 2 or greater out of a 4 point scale
- Subjects must have an OSDI© score of ≥ 15,
- Subjects must have a Grade 1 or higher staining pattern with fluorescein stain in any area of the cornea.
- The subjects may continue their current treatment for dry eye including the use of artificial tears, gels or ointments. They are to continue any topical medications for dry eye such as Cyclosporin or Lifitegrast. Subjects may continue to take chronic medications systemically including anti-inflammatory medications (aspirin, NSAIDS, Prednisone) as long as the dose and frequency is not changed throughout the study.
- Subjects may be included if they have punctual plugs present in any tear duct. If a plug comes out during the study it may be re-inserted so that the Subject is returned to their pre-treatment baseline state.
- Women of childbearing years should have pregnancy testing performed to ensure that pregnancy has not occurred during the study. Urine pregnancy screening will be performed prior to any treatment and on follow up visits until the study is completed
Exclusion
- The subject must meet the inclusion criteria as listed
- During the study they cannot have any new medications started that are anti-inflammatory in nature. This includes topical steroids, Lifitegrast, cyclosporine or systemic medications such as steroids, NSAIDS, aspirin, Doxycyline or other Macrolid antibiotics.
- Subjects cannot have a punctual plug inserted into a tear duct that has not had a plug present prior to the start of the study.
- Participation in other clinical trials during the course of this study is not permitted.
- Women who are pregnant or nursing.
Key Trial Info
Start Date :
July 25 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03280069
Start Date
July 25 2017
End Date
July 31 2019
Last Update
September 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ophthalmic Consultants of Long Island
Lynbrook, New York, United States, 11563